← Back to Search

MMR vaccination for Systemic Inflammatory Response Syndrome

Phase 3
Waitlist Available
Led By Paul L Fidel, PhD
Research Sponsored by Louisiana State University Health Sciences Center in New Orleans
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-vaccination
Awards & highlights

Study Summary

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Eligible Conditions
  • Systemic Inflammatory Response Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post-vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Induction of MDSCs
Induction of myeloid-derived suppressor cells (MDSCs)
Secondary outcome measures
COVID-19 infection positive
Health questionnaire

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MMR vaccinationExperimental Treatment1 Intervention
Subjects will be randomized to receive the MMR Vaccine subcutaneously
Group II: Placebo controlPlacebo Group1 Intervention
Subjects will be randomized to receive sterile saline given subcutaneously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MMR vaccine
2018
Completed Phase 4
~2110

Find a Location

Who is running the clinical trial?

Louisiana State University Health Sciences Center in New OrleansLead Sponsor
114 Previous Clinical Trials
44,166 Total Patients Enrolled
Parsemus FoundationUNKNOWN
Paul L Fidel, PhDPrincipal InvestigatorLouisiana State University Health Sciences Center - New Orleans

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
Paul Fidel 2020. "Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04475081.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top